Molecule Group plc Stock: price and insider trades · United Kingdom

GB00BTQLZH16GB·Mcap £56.2M

1 insider bought €105k of shares over the last 90 days, the latest filed 13 Oct 2026.

Molecule Group plc: what insiders have been doing

We have very little insider data for Molecule Group plc so far: the most recent filing dates from 13 October 2026. With so few records, no pattern can be drawn yet. Source: insider filings from RNS (LSE). Past trades are no guide to future returns.

Insider Decl.

Thresholds

n/a

Buy Volume

€104,557

1 ops. · all time

Sell Volume

n/a

Who traded when

BuySale

Brendan O’Brien1 buy

Analyst consensus: bullish or bearish?

Analysts rate Molecule Group plc Strong Buy (bullish), based on 1 analysts. Average price target: £3.08.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

as of FY 2025

FY ended December 2025 · cache

£2.06

Analyst consensus

1 analysts

Strong buy

£3.08Target £3.08(+50%)£3.08

Income statement

EBITDA-£1.3M

Net income-£1.2M-53.3% margin

Valuation

PER (forward)3745.5x

P/Book127.0x

Balance sheet & cash

Market cap£56.2M

Free Cash Flow-£1.4T

Debt / Equity3%

Profitability & ownership

ROE-24.3%

ROA-5.6%

% insiders7.6%

% institutions95.0%

Last declaration on 13 October 2026

Declarations1 total

▲

Brendan O’Brien

Chief Operating OfficerExecutives12 Oct 2026

88,346 GBP19RNS ↗

41,500 shares@ £2.12100.0% of flowXLON:AIMGB00BTQLZH16RNS:9820728

Canonical exit: 10 Jan 2027 (T+90)

1 of 1 declaration

About Molecule Group plc

Molecule Group plc is a publicly traded company on the London Stock Exchange, specializing in the development of innovative solutions in the biotechnology sector. It focuses on research and commercialization of products to enhance human health.